Triglav Skladi D.O.O. Buys Shares of 5,000 Danaher Corporation (NYSE:DHR)

Key Points

• Triglav Skladi D.O.O. acquired a new stake in Danaher Corporation, purchasing 5,000 shares valued at approximately $1,025,000 in the first quarter.
• The stock currently has a consensus rating of "Moderate Buy" with a target price of $247.61, with 18 analysts giving it a buy rating.
• Danaher reported a net margin of 14.21% and revenue of $5.94 billion for the last quarter, exceeding analysts' estimates.

Triglav Skladi D.O.O. bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,000 shares of the conglomerate's stock, valued at approximately $1,025,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. FAS Wealth Partners Inc. grew its stake in shares of Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after purchasing an additional 1,639 shares during the last quarter. MGO One Seven LLC lifted its position in Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after acquiring an additional 20,813 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in Danaher in the 1st quarter valued at about $539,000. Horizon Financial Services LLC lifted its position in Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after acquiring an additional 8,160 shares in the last quarter. Finally, EFG Asset Management Americas Corp. increased its stake in Danaher by 13.1% in the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock valued at $7,396,000 after buying an additional 4,191 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on DHR. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. HSBC decreased their price target on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Guggenheim restated a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Argus decreased their price target on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Finally, Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Danaher currently has an average rating of "Moderate Buy" and an average price target of $247.61.

Danaher Trading Up 0.3%

Shares of DHR traded up $0.62 during midday trading on Friday, hitting $210.84. The stock had a trading volume of 3,210,213 shares, compared to its average volume of 4,658,279. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The firm has a market cap of $150.97 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock's 50 day moving average is $199.94 and its 200 day moving average is $199.71.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the prior year, the firm posted $1.72 earnings per share. The business's revenue for the quarter was up 3.4% on a year-over-year basis. As a group, analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.